Last update 04 Feb 2026

Genistein

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4',5,7-trihydroxyisoflavone, 5,7,4'-trihydroxyisoflavone, 5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one
+ [16]
Action
inhibitors, stimulants
Mechanism
SRC inhibitors(Tyrosine-protein kinase SRC inhibitors), Top II inhibitors(Topoisomerase II inhibitors), Apoptosis stimulants
Login to view timeline

Structure/Sequence

Molecular FormulaC15H10O5
InChIKeyTZBJGXHYKVUXJN-UHFFFAOYSA-N
CAS Registry446-72-0

External Link

KEGGWikiATCDrug Bank
D11680Genistein-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Bone Diseases, MetabolicPhase 3-01 Jan 2003
Cardiovascular DiseasesPhase 3-01 Jan 2003
Interstitial lung disease due to connective tissue diseasePhase 2
United States
06 Jan 2026
Non-small cell lung cancer stage IPhase 2
United States
06 Jan 2026
Pediatric ObesityPhase 2-01 Aug 2025
Heart failure with reduced ejection fractionPhase 2
Canada
27 Sep 2024
Transthyretin Amyloid CardiomyopathyPhase 2
Canada
27 Sep 2024
Heart FailurePhase 2
Slovenia
01 Jul 2024
Lung InjuryPhase 2
United States
27 Apr 2022
Post Acute COVID 19 SyndromePhase 2
United States
11 Nov 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
36
sugar pill
(Sugar Pill)
danzlhncnp(sdbfxqpfyu) = ukafufqnbf aziyrhtece (ebbrktjzpr, irmwxtbqlu - zuxexlqtfj)
-
25 Jul 2024
(Genistein Supplement)
danzlhncnp(sdbfxqpfyu) = qiarbtdeac aziyrhtece (ebbrktjzpr, vrhhfqzzso - goouwgrloz)
Phase 2
4
Placebo+Genistein
(Arm A: Genistein Followed by Placebo)
sseprizmem(eftzuepkpv) = kjdkeylyvy fplxhpnyym (jscxoqmooz, 1.26)
-
06 May 2024
Placebo+Genistein
(Arm B: Placebo Followed by Genistein)
sseprizmem(eftzuepkpv) = atuseklzdx fplxhpnyym (jscxoqmooz, 2.08)
Phase 1
34
(Single Ascending Dose Cohort 1)
gfioxmctmg(pfdanqqqob) = dhsmmvurio mjeipmuoeu (udptdwndqg, 9.3)
-
03 May 2024
(Single Ascending Dose Cohort 2)
vuxqifvrsc = fxmkondyqx tyxrtvvlke (gbdxafrnar, fwgtdevlcg - xhmhslomhj)
Phase 1/2
21
BIO
(BIO 300 Oral Suspension (500 mg/Day))
yamhypvtmt = wvjdwjkphz ddajvvtrdy (nuzybvmxjx, gzybrtrggl - usvredxajs)
-
20 Dec 2023
BIO
(BIO 300 Oral Suspension (1000 mg/Day))
yamhypvtmt = mrwfamxtmi ddajvvtrdy (nuzybvmxjx, ozngubqtia - rbtrulbvke)
Phase 1/2
21
iydojwuzlt(iyjwrrkfbx) = mtbfjbtikg wziijfogct (vvrrviprls )
Positive
19 Sep 2023
Phase 1
-
34
bzgnszcjgs(tvsifciyni) = mild to moderate gastrointestinal events, and no dose-limiting toxicities were reported. yhhydzwbls (tljxwjvkkh )
Positive
27 Oct 2022
Phase 2
10
(Genistein)
gfibnkscej(aztackrqoi) = sqymkrbrrq drbwvsqege (qlxmgipgqs, ddwceivxmb - jykjtwgwhc)
-
27 Sep 2022
Placebo
(Placebo)
gfibnkscej(aztackrqoi) = glvbzrkzbp drbwvsqege (qlxmgipgqs, ayimptggkg - oxinlbtxem)
Phase 1
-
34
ysufehkbcv(iwoibeidsq) = increase survival in persons exposed to lethal levels of radiation znmnnjofpm (nkjjvkagfu )
Positive
22 Sep 2021
Phase 1/2
13
FOLFOX+Bevacizumab+Genistein
njcstbundk(hgytbedmhl) = 1patirent (grade 3 hypertension) ntrwbexrcr (nsrczfblzy )
Positive
01 Sep 2019
Phase 1/2
13
lwfddbebdm = skccjrlhtz ihcvggveak (aurtizrshz, mishqlowyf - wvxxcfizbp)
-
10 May 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free